Latest Videos
What sources are used, and should be used in China, to determine what targeted, anti-cancer therapies should be deployed in genomic alterations detected by NGS sequencing? “Broad molecular profiling” is already recommended for 1st line ...
What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE?
In what important ways does NGS and CGP address the fundamental changes that systemic cancer treatment is undergoing toward the use of molecularly targeted drugs prescribed to patients across multiple tumor types?
For which solid tumors do you find NGS genomic profiling to be most valuable for identifying molecular drivers that can reliably guide the use of targeted therapy?
In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do initial studies using BRAF V600 to guide vemurafenib and cetuximab in patients with colorectal cancer show? Does your genomic profiling service ...
What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with ...
What kind of specific, actionable information is contained on a FoundationOne CGP report?
What kind of specific, actionable information is contained on a FoundationOne CGP report?
How do you select patients with solid tumors that are appropriate for NGS? Is it useful just for patients with cancer at time of presentation? Can it be used for patients under treatment? For assessment of tumors in patients who have relapsed?
What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE?
In what types of solid tumors has mutation-directed therapy been shown to improve patient outcomes, including progression-free survival and overall (OS)?
What is FoundationOne Heme? How accurate are its detection rates and how is it being used to detect genomic alterations that can impact diagnosis, therapy selection and prognosis in hematologic cancers?
What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with ...